Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : National Research Development Fund, Hungary | Meditop Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 16, 2022
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : National Research Development Fund, Hungary | Meditop Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study
Details : Phase 3, RESUME-1, clinical study of tolperisone for the relief of muscle spasm associated with acute, painful musculoskeletal conditions, failed to meet its primary and key secondary endpoints.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study
Details : Company completed its Phase 3 RESUME-1 Study of tolperisone for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. The primary endpoint showed patient reported pain at day 14 due to acute back spasm.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2021
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurana Pharmaceuticals to Present at Napa Pain Conference and PAIN Week
Details : The scientific abstracts presented at both congresses demonstrate the potential benefit of tolperisone as a non-opioid, non-drowsy, non-central nervous system impairing skeletal muscle relaxant.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The publication reports results from the Phase 1, threeway, randomized, blinded, three-period crossover study that evaluated cyclobenzaprine in neuromuscular conditions.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2020
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research
Details : The published clinical data demonstrates the potential benefit of tolperisone in the treatment of acute and painful muscle spasms. The data supports and strengthens a planned Phase 3 RESUME-1 study, for which Neurana will begin enrollment imminently.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study
Details : The study is a randomized, 4-period, crossover study designed to investigate the effects of tolperisone on measures of drowsiness and cognitive function compared to cyclobenzaprine and placebo.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 PK Study of Tolperisone in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2020
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Tolperisone on Measures of Drowsiness and Cognitive Function
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : Tolperisone,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable